Literature DB >> 14980978

Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: putative roles of hypoxia-inducible factor-1.

Ding-I Yang1, Shang-Der Chen, Ya-Ting Yang, Tzyh-Chwen Ju, Jin-Ming Xu, Chung Y Hsu.   

Abstract

1. We tested whether pretreatment of reagents known to induce hypoxia-inducible factor-1 (HIF-1) may confer chemoresistance against cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) to rat C6 glioma cells. We also studied which cytotoxic mechanism(s) of chloroethylnitrosoureas could be neutralized by cobalt preconditioning. 2. Preconditioning of rat C6 glioma cells with cobalt chloride (300 microm, 2 h) induced HIF-1 binding activity based on electrophoretic mobility shift assay (EMSA). Results from Western blotting confirmed a heightened HIF-1alpha level upon cobalt chloride exposure (300-400 microm, 2 h). Cobalt chloride (300 microm) pretreatment for 2 h substantially neutralized BCNU toxicity, leading to increases in glioma cell survival based on MTT assay. In addition, pre-exposure of C6 cells with desferrioxamine (DFO; 400 microm, 3 h), an iron chelator known to activate HIF-1, also induced HIF-1 binding and rendered the glioma cells resistant to cytotoxicity of BCNU. 3. Pre-incubation with cobalt chloride abolished the cytotoxicity of several carbamoylating agents including 2-chloroethyl isocyanate and cyclohexyl isocyanate, the respective carbamoylating metabolites of BCNU and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. The protective effect of cobalt exposure, however, was not observed when cells were challenged with alkylating agents including temozolomide. 4. Cadmium chloride (50 microm) effectively reversed cobalt-induced HIF-1 activation. Correspondingly, cadmium chloride suppressed carbamoylating chemoresistance mediated by cobalt chloride pretreatment. Furthermore, both double-stranded oligodeoxynucleotide (ODN) decoy with HIF-1 cognate sequence and antisense phosphorothioate ODNs against HIF-1alpha partially abolished the carbamoylating chemoresistance associated with cobalt preconditioning. 5. Our results suggest that cobalt- or DFO-preconditioning may enhance glioma carbamoylating chemoresistance that is dependent, at least in part, on induction of HIF-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14980978      PMCID: PMC1574263          DOI: 10.1038/sj.bjp.0705687

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines.

Authors:  M M Heim; W Eberhardt; S Seeber; M R Müller
Journal:  J Cancer Res Clin Oncol       Date:  2000-04       Impact factor: 4.553

2.  Novel molecular mechanism of increased myocardial endothelin-1 expression in the failing heart involving the transcriptional factor hypoxia-inducible factor-1alpha induced for impaired myocardial energy metabolism.

Authors:  Y Kakinuma; T Miyauchi; K Yuki; N Murakoshi; K Goto; I Yamaguchi
Journal:  Circulation       Date:  2001-05-15       Impact factor: 29.690

3.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation.

Authors:  G L Semenza; G L Wang
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

4.  Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1-nitrosourea in c6 glioma cells.

Authors:  J H Yin; D I Yang; H Chou; E M Thompson; J Xu; C Y Hsu
Journal:  J Pharmacol Exp Ther       Date:  2001-04       Impact factor: 4.030

5.  Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin.

Authors:  K Zaman; H Ryu; D Hall; K O'Donovan; K I Lin; M P Miller; J C Marquis; J M Baraban; G L Semenza; R R Ratan
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

6.  Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy.

Authors:  C L Nutt; M Noble; A F Chambers; J G Cairncross
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

7.  iNOS expression inhibits hypoxia-inducible factor-1 activity.

Authors:  J H Yin; D I Yang; G Ku; C Y Hsu
Journal:  Biochem Biophys Res Commun       Date:  2000-12-09       Impact factor: 3.575

8.  Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas.

Authors:  P G Penketh; K Shyam; A C Sartorelli
Journal:  Biochem Pharmacol       Date:  2000-02-01       Impact factor: 5.858

9.  Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide.

Authors:  H Kimura; A Weisz; Y Kurashima; K Hashimoto; T Ogura; F D'Acquisto; R Addeo; M Makuuchi; H Esumi
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

10.  Cadmium blocks hypoxia-inducible factor (HIF)-1-mediated response to hypoxia by stimulating the proteasome-dependent degradation of HIF-1alpha.

Authors:  Y S Chun; E Choi; G T Kim; H Choi; C H Kim; M J Lee; M S Kim; J W Park
Journal:  Eur J Biochem       Date:  2000-07
View more
  7 in total

1.  Ethyl 3,4-dihydroxy benzoate, a unique preconditioning agent for alleviating hypoxia-mediated oxidative damage in L6 myoblasts cells.

Authors:  Charu Nimker; Gurpreet Kaur; Anshula Revo; Pooja Chaudhary; Anju Bansal
Journal:  J Physiol Sci       Date:  2014-11-08       Impact factor: 2.781

2.  Hydrogen sulfide inhibits the translational expression of hypoxia-inducible factor-1α.

Authors:  Bo Wu; Huajian Teng; Guangdong Yang; Lingyun Wu; Rui Wang
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

3.  Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.

Authors:  Umar Akbar; Terreia Jones; Jon Winestone; Madison Michael; Atul Shukla; Yichun Sun; Christopher Duntsch
Journal:  J Neurooncol       Date:  2009-04-01       Impact factor: 4.130

Review 4.  Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.

Authors:  Erwin G Van Meir; Binghe Wang; Sarah K Burroughs; Stefan Kaluz; Danzhu Wang; Ke Wang
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

Review 5.  Emerging Roles of Inhibitor of Differentiation-1 in Alzheimer's Disease: Cell Cycle Reentry and Beyond.

Authors:  Shang-Der Chen; Jenq-Lin Yang; Yi-Chun Lin; A-Ching Chao; Ding-I Yang
Journal:  Cells       Date:  2020-07-21       Impact factor: 6.600

6.  Hypoxia preconditioning protection of corneal stromal cells requires HIF1alpha but not VEGF.

Authors:  Dongmei Xing; Joseph A Bonanno
Journal:  Mol Vis       Date:  2009-05-18       Impact factor: 2.367

7.  A drug combination targeting hypoxia induced chemoresistance and stemness in glioma cells.

Authors:  Akansha Jalota; Mukesh Kumar; Bhudev C Das; Ajay K Yadav; Kunzang Chosdol; Subrata Sinha
Journal:  Oncotarget       Date:  2018-04-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.